Corbus Pharmaceuticals Holdings, Inc

Short Term Long Term Short Term Comparison Long Term Comparison

CRBP
1d4.58%
1w14.01%
1m-2.20%
1y345.46%
CRBP
1y345.46%
5y-80.25%
10y0.00%
20y0.00%

Bitcoin
-0.82%
-9.09%
-6.40%
106.24%
Bitcoin
106.24%
1,146.32%
11,770.30%
0.00%

Ethereum
-0.90%
-11.75%
-14.49%
45.57%
Ethereum
45.57%
1,828.08%
0.00%
0.00%

Gold
0.26%
2.56%
11.41%
20.52%
Gold
20.52%
88.92%
85.82%
499.35%

Silver
0.47%
4.25%
15.38%
14.30%
Silver
14.30%
94.94%
48.08%
306.93%

Apple
-2.19%
1.78%
0.04%
5.09%
Apple
5.09%
260.11%
-66.73%
39,041.00%

Amazon
-1.68%
-1.44%
4.92%
78.52%
Amazon
78.52%
96.45%
-43.46%
7,943.96%

Microsoft
-1.96%
-2.97%
-0.67%
45.75%
Microsoft
45.75%
259.81%
923.86%
2,532.12%

S&P 500
-1.20%
-2.84%
-1.08%
22.34%
S&P 500
22.34%
74.12%
171.80%
346.13%

Dow & Jones
-0.65%
-2.95%
-2.53%
11.36%
Dow & Jones
11.36%
42.65%
129.74%
261.03%

ATH

ATH Price$310.50
ATH Date2017-03-20
% since ATH-86.24%
% to ATH626.83%

ATL

ATL Price$2.14
ATL Date2023-03-10
% from ATL1,896.26%
Last Low Price$2.14
Last Low Date2023-03-10
% From Last Low1,896.26%

IPO

IPO Price$3.00
% Current ROI USD1,424.00%
ATH Price$310.50
% ROI ATH 1,450,934.58%

[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CRBP"]

Key Data [addtoany]

Current price	$42.72
Sector	Healthcare
Industry	Biotechnology
Today's High/Low	$42.96/$39.58
Volume	347,431.00
Previous Close	$40.85
52 Week High/Low	$49.8699/$3.0334
Market Cap	429,219,104.00
P/E Ratio	0
Forward P/E 1 Yr.	$0.00
Earnings Per Share(EPS)	$-5.12
Annualized Dividend	$0

$42.72

[addtoany]

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer.
Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus.
The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Annual Data \| Millions of US $ except per share data	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Cash on hand	$31.75	$41.75	$62.54	$14.99	$12.34	-	-	-
Receivables	$2.68	-	-	$1	-	$1.33	-	-
Inventory	-	-	$0	$0	$0	$0	-	-
Pre-Paid Expenses	-	-	-	-	-	-	-	-
Other Current Assets	$3.72	$2.49	$2.81	$1.26	$0.38	$0.27	$0300000	-
Total Current Assets	$38.15	$44.24	$65.50	$17.40	$12.71	$6.53	-	-
Property, Plant, And Equipment	$10.90	$2.71	$1.43	$0.44	$0.12	$0.05	-	-
Long-Term Investments	-	-	-	-	-	-	-	-
Goodwill And Intangible Assets	-	-	$0	$0	$0	$0	-	-
Other Long-Term Assets	$0.08	$0.04	$0.04	$0.05	$0.04	$0.01	-	-
Total Long-Term Assets	$10.99	$2.75	$1.47	$0.49	$0.16	-	-	-
Total Assets	$49.14	$46.99	$66.98	$17.89	$12.88	$6.60	$0.31	-
Total Current Liabilities	$34.89	$18.09	$8.20	$8.90	$3.63	$0.74	$0.65	-
Long Term Debt	-	-	$0	$0500000	$0	$0	$0.33	-
Other Non-Current Liabilities	-	$1.38	$0.99	$0.07	$0.26	$0463200	-	-
Total Long Term Liabilities	$8.10	$1.38	$0.99	$0.07	$0.26	-	-	-
Total Liabilities	$42.98	$19.47	$9.19	$8.97	$3.89	$0.74	$0.98	-
Common Stock Net	$0646700	$0572500	$0556000	$0446800	$0376100	$0300000	$0100000	-
Retained Earnings (Accumulated Deficit)	$-192.82	$-121.37	$-65.70	$-33.28	$-13.28	$-4.43	-	-
Comprehensive Income	-	-	$0	$0	$0	$5.86	-	-
Other Share Holders Equity	-	-	-	-	-	-	-	-
Share Holder Equity	$6.16	$27.52	$57.78	$8.92	$8.99	$5.86	-	-
Total Liabilities And Share Holders Equity	$49.14	$46.99	$66.98	$17.89	$12.88	-	-	-

Annual Data \| Millions of US $ except per share data	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Revenue	$36.14	$4.82	$2.44	$1.91	$0.65	$0	-	-
Cost Of Goods Sold	$89.60	$48.61	$26.04	$15.44	$5.89	$1.26	-	-
Gross Profit	-	-	-	-	-	-	-	-
Research And Development Expenses	$89.60	$48.61	$26.04	$15.44	$5.89	$-1.26	$0.21	-
SG&A Expenses	$23.64	$12.96	$8.96	$6.46	$3.61	$-1.39	$0.56	-
Other Operating Income Or Expenses	-	-	-	-	-	-	-	-
Operating Expenses	$113.25	$61.57	$35	$21.90	$9.50	$-2.65	-	-
Operating Income	$-77.10	$-56.75	$-32.56	$-19.99	$-8.85	$-2.65	-	-
Total Non-Operating Income/Expense	$5.65	$0.09	$-0.04	$-0.01	$0539400	$0.13	-	-
Pre-Tax Income	$-71.45	$-55.67	$-32.42	$-20	$-8.85	$-2.54	-	-
Income Taxes	-	$0	$0	$0	$0	$0	-	-
Income After Taxes	-	$0	$0	$0	$0	$0	-	-
Other Income	-	-	-	-	-	-	-	-
Income From Continuous Operations	$-71.45	$-55.67	$-32.42	$-20	$-8.85	$-2.54	-	-
Income From Discontinued Operations	-	-	-	-	-	-	-	-
Net Income	$-71.45	$-55.67	$-32.42	$-20	$-8.85	$-2.54	-	-
EBITDA	-	-	-	-	-	-	-	-
EBIT	$-77.10	$-56.75	$-32.56	$-19.99	$-8.85	$-2.65	-	-
Basic Shares Outstanding	-	-	-	-	-	-	-	-
Shares Outstanding	$64	$57	$55.60	$41	$37.61	$20	$7	$7
Basic EPS	-	-	-	-	-	-	-	-
EPS - Earnings Per Share	-	-	-	-	-	-	-	-

Annual Data \| Millions of US $ except per share data	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Net Income/Loss	$-71.45	$-55.67	$-32.42	$-20	$-8.85	$-2.54	-	-
Total Depreciation And Amortization - Cash Flow	$1.23	$0.49	$0.26	$0.09	$0.04	$0.01	-	-
Change In Accounts Receivable	$5	$12.50	$1	$-1	$-1	$-1	-	-
Change In Inventories	-	-	$0	$0	$0	$0	-	-
Cash Flow From Operating Activities	$-45.72	$-30.07	$-27.80	$-13.57	$-4.62	$-2.36	-	-
Cash Flow From Investing Activities	$-2.74	$-2.30	$-0.71	$-0.35	$-0.11	$-0.06	-	-
Debt Issuance/Retirement Net - Total	$0.36	$0.06	$0.06	$0.11	$-0.49	$-1.92	-	-
Total Common And Preferred Stock Dividends Paid	-	-	$0	$0	$0	$0	-	-
Financial Activities - Other	$-2.57	$-0.69	$-2.94	$-0.06	$-0.51	$-1.87	-	-
Cash Flow From Financial Activities	$38.46	$11.42	$76.01	$16.74	$10.84	$8.38	$0.13	-
Net Cash Flow	$-10	$-20.95	$47.50	$2.82	$6.10	$5.96	-	-
Common Stock Dividends Paid	-	-	$0	$0	$0	$0	-	-